Pivotal pharmacokinetic trial of a hormone therapy, TX 12001HR, for the treatment of menopausal syndrome.
Latest Information Update: 09 Jan 2014
Price :
$35 *
At a glance
- Drugs Estradiol/progesterone (Primary) ; Estradiol; Progesterone
- Indications Menopausal syndrome
- Focus Pharmacokinetics; Registrational
- Sponsors TherapeuticsMD
- 12 Oct 2013 Primary endpoint 'Peak-drug-concentration' has been met according to results presented at the 24th Annual Meeting of the North American Menopause Society.
- 12 Oct 2013 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has been met according to results presented at the 24th Annual Meeting of the North American Menopause Society.
- 09 Oct 2013 Results have been presented at The North American Menopause Society 2013 Annual Meeting according to a TherapeuticsMD media release. Results were also summarised in the media release.